Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat for acute lung injury associated with systemic inflammatory response syndrome
ChiCTR-TRC-11001555Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sivelestat in acute lung injury (ALI) and Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Lung injury score. Started Sep 2005; status: completed.
02
Drugs
sivelestat
03
Conditions
acute lung injury (ALI)Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on ChiCTR-TRC-11001555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001555.